1. Home
  2. ULCC vs DVAX Comparison

ULCC vs DVAX Comparison

Compare ULCC & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frontier Group Holdings Inc.

ULCC

Frontier Group Holdings Inc.

HOLD

Current Price

$5.81

Market Cap

1.1B

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.84

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULCC
DVAX
Founded
1994
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
ULCC
DVAX
Price
$5.81
$10.84
Analyst Decision
Hold
Buy
Analyst Count
10
4
Target Price
$5.56
$26.50
AVG Volume (30 Days)
4.7M
1.5M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,729,000,000.00
$330,514,000.00
Revenue This Year
$0.37
$24.63
Revenue Next Year
$14.59
$15.85
P/E Ratio
N/A
N/A
Revenue Growth
1.77
26.73
52 Week Low
$2.89
$9.20
52 Week High
$10.26
$14.63

Technical Indicators

Market Signals
Indicator
ULCC
DVAX
Relative Strength Index (RSI) 78.64 48.59
Support Level $4.71 $10.71
Resistance Level $6.02 $11.00
Average True Range (ATR) 0.33 0.26
MACD 0.15 -0.06
Stochastic Oscillator 90.28 22.63

Price Performance

Historical Comparison
ULCC
DVAX

About ULCC Frontier Group Holdings Inc.

Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: